检索历史 清除

目的:了解北京市户籍居民病毒性肝炎死亡情况，为北京市病毒性肝炎防控提供参考依据。方法:计算死亡率、标化死亡率、寿命损失年数（years of life lost，YLL）率、标化YLL率等指标，分析2005—2020年北京市户籍居民病毒性肝炎的死亡特征。结果:2005—2020年北京市居民病毒性肝炎的死亡率、标化死亡率、YLL率、标化YLL率均呈下降趋势。北京市病毒性肝炎死亡病例以慢性（91.83%）为主，慢性中又以乙肝（76.52%）为主。2019年北京市急性病毒性肝炎的标化死亡率低于全球和全国，与日本、韩国基本持平，高于新加坡和全球高收入国家；标化YLL率在所选取的国家和地区中，只高于新加坡。结论:十六年来，北京市病毒性肝炎防治取得了巨大成效，急性病毒性肝炎死亡状况与亚太高收入国家基本持平，但仍与健康期望寿命最高的新加坡有所差距。慢性病毒性肝炎仍为病毒性肝炎防控的重中之重，还应持续扩大筛查力度，提高公众早筛意识，提升诊断率和治疗率，降低发病率和死亡率。

Objective:To investigate the deaths induced by viral hepatitis among registered residents in Beijing, so as to provide reference for prevention and control of viral hepatitis in Beijing.Methods:The mortality rate, standardized mortality rate, years of life lost (YLL) rate and standardized YLL rate were calculated to analyze the death characteristics of viral hepatitis among registered residents in Beijing from 2005 to 2020.Results:From 2005 to 2020, the mortality rate, standardized mortality rate, YLL rate and standardized YLL rate of residents in Beijing showed trends of decreasing. In Beijing, the deaths were mainly induced by chronic viral hepatitis (91.83%), and hepatitis B was mainly cause among chronic hepatitis (76.52%). In 2019, the standardized mortality rate of acute viral hepatitis in Beijing was lower than that of the world and China, basically the same as that of Japan and South Korea, and higher than that of Singapore and high-income countries in the world. Among the selected countries and regions, the standardized YLL rate was higher than Singapore only.Conclusions:In the past 16 years, the prevention and treatment of viral hepatitis in Beijing obtained great achievements. The death rate of acute viral hepatitis was basically the same as that of high-income countries in Asia Pacific region, but still lags behind Singapore which has the highest healthy life expectancy. Chronic viral hepatitis is still the top priority of viral hepatitis prevention and control, and screening efforts should be continued to expand and improve public awareness of early screening, diagnosis and treatment rates, and reduce morbidity and mortality.